Stockscreener 앱 받기
767.76
1.35%
10.22
Lilly Eli Co 주식(LLY)의 최신 뉴스
Novo Nordisk raises Eli Lilly post CagriSema data (NVO:NYSE) - Seeking Alpha
2 Dividend-Growth Stocks That Billionaire Izzy Englander Loves - The Motley Fool
Novo obesity data positive for Eli Lilly and Amgen, says UBS - Yahoo Finance
FDA says knockoff versions of Lilly obesity drug must come off the market - Wyoming Tribune
Is Now a Good Time to Buy the Dip in Eli Lilly Stock? - AOL
FDA approves Eli Lilly’s obesity medication for obstructive sleep apnea - ABC News
The FDA just approved Eli Lilly's Zepbound for sleep apnea — and Medicare coverage could be next - MSN
Eli Lilly given green light in US to treat sleep disorder with weight-loss drug - Financial Times
Lilly's weight-loss treatment Zepbound becomes first FDA-approved drug for sleep apnea - Reuters
Lilly's weight-loss drug Zepbound wins US FDA approval for sleep apnea By Reuters - Investing.com
Eli Lilly’s obesity drug Zepbound approved to treat sleep apnea in U.S. - STAT
Eli Lilly's Zepbound gains sleep apnea indication (LLY:NYSE) - Seeking Alpha
Lilly's weight-loss drug Zepbound wins US FDA approval for sleep apnea - The Denver Gazette
Lilly’s Zepbound Grabs First Drug Approval for Sleep Apnea in US - Bloomberg
FDA approves Eli Lilly's weight loss drug Zepbound for sleep apnea, expanding use in U.S. - CNBC
FDA approves Zepbound® (tirzepatide) as the first and only prescription medicine for moderate-to-severe obstructive sleep apnea in adults with obesity - Investors | Eli Lilly and Company
Eli Lilly and Company (NYSE:LLY) Trading 4.2% HigherHere's Why - MarketBeat
Nvidia, Eli Lilly lead Friday's market cap stock movers By Investing.com - Investing.com Canada
Nvidia, Eli Lilly lead Friday's market cap stock movers - Investing.com India
Lilly Cements Weight Loss Lead After Novo Trial Setback - Bloomberg
Eli Lilly: Improved Competitive Position In Obesity Market, But Strong Execution Is A Must Now - Seeking Alpha
Why Novo Nordisk Stock Got Destroyed Today, but Eli Lilly and Viking Stocks Are Up - The Motley Fool
Novo Nordisk’s next-generation weight-loss drug matches Lilly’s Zepbound in major trial, but doesn’t surpass it - CNN
Eli Lilly and Company (NYSE:LLY) Shares Gap UpHere's What Happened - MarketBeat
Eli Lilly, Avago lead market cap stock movers this Friday - Investing.com
In weight loss battle, Novo and Lilly face growing offensive from licensed copies - Reuters
LLY Stock Up as FDA Removes Mounjaro, Zepbound From Shortage List - Yahoo Finance
Stocks to Watch Friday: Trump Media, Novo Nordisk, Eli Lilly, Tesla - The Wall Street Journal
Eli Lilly shares reiterate buy rating on Phase 3 study results - Investing.com
Citi Reiterates Buy Rating on Eli Lilly (LLY) - StreetInsider.com
FedEx, Eli Lilly, Occidental rise premarket; Nike, Novo Nordisk fall - Investing.com
FDA confirms end of Eli Lilly’s tirzepatide shortage after re-evaluation - Yahoo Finance
Eli Lilly (LLY) stock: Why It’s a strong buy amid breakthrough developments - The Africa Logistics
Bernstein optimistic on Eli Lilly shares despite limited near-term impact from Tirzepatide - Investing.com
Novo Nordisk sinks on latest data, Lilly gains - Investing.com
FDA finalizes decision to end Lilly's GLP-1 shortage, analysts predict Novo will be next - Yahoo Finance
US FDA says Lilly's weight-loss drug shortage is resolved - Reuters.com
Eli Lilly & Co. stock underperforms Thursday when compared to competitors - MarketWatch
Jim Cramer on Eli Lilly and Company (LLY): ‘I See Things Going Back To Normal For Eli Lilly’ - Insider Monkey
Eli Lily GLP-1 shortage ends, FDA says: Hims & Hers stock falls - Yahoo Finance
Eli Lilly and Company (NYSE:LLY) Shares Down 1.2%Should You Sell? - MarketBeat
US FDA says Lilly’s weight-loss drug shortage is resolved - CNN
Eli Lilly dips despite FDA confirming shortage of GLP-1 tirzepatide is over - Investing.com
Eli Lilly’s (NYSE:LLY) Zepbound Shortage Over, Says FDA - TipRanks
Lilly’s US Weight-Loss Drug Shortage Ends, Curtailing Copies - Bloomberg
FDA Says Shortage of Eli Lilly’s Zepbound is Over, But Gives Compounders a Grace Period - Yahoo! Voices
Lilly’s US Weight-Loss Drug Shortage Ends, Curtailing Copycats - The Business of Fashion
Lilly’s US weight-loss drug shortage ends, curtailing copycats - Detroit News
Eli Lilly’s Zepbound Shortage Is Officially Over, FDA Says - Yahoo! Voices
Eli Lilly (LLY) Stock Price Prediction and Forecast 2025-2030 - 24/7 Wall St.
Zealand Pharma And Eli Lilly: Strategic Focus On Weight Management And Future Outlook - Seeking Alpha
This Is Huge News for Eli Lilly Investors - The Motley Fool
17.83%
0.62%
자본화:
|
볼륨(24시간):